Direct targeting with B-Raf kinase inhibitors such as vemurafenib or dabrafenib is an effective new treatment option and has been approved for advanced malignant melanomas harboring the BRAF V600E mutation [5]. The gene discussed is BRAF; the disease is melanoma.